Valuation: Armata Pharmaceuticals, Inc.

Market Cap 166M 145M 134M 123M 232M 15.94B 237M 1.6B 628M 7.81B 622M 608M 26.88B P/E 2026 *
-1.19x
P/E 2027 * -3.37x
Enterprise Value 166M 145M 134M 123M 232M 15.94B 237M 1.6B 628M 7.81B 622M 608M 26.88B EV / Sales 2026 *
75.3x
EV / Sales 2027 * 60.2x
Free-Float
31.49%
Yield 2026 *
-
Yield 2027 * -
1 day+19.95%
1 week+5.87%
Current month-30.40%
1 month-36.30%
3 months-60.78%
6 months-29.53%
Current year-28.18%
1 week 3.48
Extreme 3.48
4.55
1 month 3.48
Extreme 3.48
7.63
Current year 3.48
Extreme 3.48
14.98
1 year 2.32
Extreme 2.32
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 2023-07-10
Director of Finance/CFO 42 2024-08-15
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 2019-05-08
Director/Board Member 66 2020-02-11
Director/Board Member 51 2020-02-11
Date Insider Type Main position Quantity % Market Cap.
7/10/26 Tax

Chief Executive Officer

-14,041 0.0382%
4/24/26 Free

Director

51,280 0.1400%
3/14/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
+19.95%+5.87%+87.92%+292.17% 166M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -0.50%-1.78%+45.28%+194.86% 23.37B
Weighted average by Cap. -2.78%-2.35%+39.58%+143.23%

Financials

2026 *2027 *
Net sales 2.2M 1.92M 1.77M 1.64M 3.08M 212M 3.15M 21.21M 8.34M 104M 8.26M 8.08M 357M 2.75M 2.4M 2.22M 2.04M 3.85M 265M 3.94M 26.51M 10.43M 130M 10.33M 10.1M 446M
Net income -172M -150M -139M -128M -241M -16.55B -246M -1.66B -652M -8.11B -646M -631M -27.91B -66.35M -57.98M -53.51M -49.32M -92.96M -6.39B -95.02M -640M -252M -3.13B -249M -244M -10.77B
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
26-07-17 US$4.510 +19.95% 271,343
26-07-16 US$3.760 -5.76% 342,673
26-07-15 US$3.990 +1.79% 139,871
26-07-14 US$3.920 -1.26% 149,037
26-07-13 US$3.970 -6.81% 160,811
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.510USD
Average target price
17.50USD
Spread / Average Target
+288.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock